“The physician-initiated research being presented at this year’s Boswick Symposium underscores how the RECELL® System is advancing treatment of burn wounds, both as a monotherapy and in combination with complementary technologies,” said Dr.
RECELL® System Abstracts
- Autologous keratinocyte suspension in conjunction with fibrin sealant for the treatment of partial thickness burns. Author:
E. Brown ,Texas Tech University HSC School of Medicine ,Lubbock, TX - Utilizing glabrous skin from the palm to source autologous regenerative epidermal suspension for deep partial thickness palmar burns. Author:
P. Fidler , Burn andReconstructive Centers of America - A Retrospective Review of Clinical Outcomes in Superficial and Deep Second-Degree Burn Patients treated with Autologous Skin Cell Suspension (RECELL) and Split Thickness
Skin Graft . Author: K. Henry, Jacobi Medical Center,Bronx, New York - Simplifying the Treatment Algorithm by Reducing Number of Autografting Procedures: Use of ASCS for Thermal Burn Injuries. Author:
W. Hickerson , AVITA Medical Consultant - The holy grail? Experience with autologous skin cell suspension combined with a poly-lactic acid dressing. Author:
A. Khandelwal , MD, FACS, FICS, Akron Children’s Hospital,Akron, OH - Biodegradable Temporizing Matrix and Autologous Skin Cell Suspension in Necrotizing Soft Tissue Infection: A Case Report. Author:
A. Raghuram ,Texas Tech University HSC School of Medicine ,Lubbock, TX
For more information about the RECELL System, please visit www.avitamedical.com.
ABOUT
AVITA Medical’s first
In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds, and aesthetics. The RECELL System is TGA-registered in
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this press release include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the company’s control. Investors should not place considerable reliance on the forward-looking statements contained in this press release. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.
This press release was authorized by the review committee of
FOR FURTHER INFORMATION:
Phone +1-615-414-8668 christycurran@sambrown.com O.U.S. Media Phone +61 (0)3 9620 3333 Mobile +61 (0)411 402 737 rudim@monsoon.com.au | Investors ICR Westwicke Phone +1-415-202-5678 caroline.corner@westwicke.com |
Source:
2022 GlobeNewswire, Inc., source